文献速递糖尿病

循环FGF21浓度、空腹血糖与2型糖尿病风险:PREVEND研究结果

Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

在PREVEND研究的5244名参与者中,中位循环FGF21浓度为860 pg/mL,随访7.3年期间299人发生2型糖尿病。完全校正后,FGF21每翻倍与2型糖尿病风险升高相关(HR 1.26,95%CI 1.06-1.51,P=0.008),且该关联受空腹血糖效应修饰,在较低空腹血糖者中更强。

要点

  • 循环FGF21每翻倍与2型糖尿病风险升高相关(HR 1.26,95%CI 1.06-1.51,P=0.008)。
  • FGF21与2型糖尿病的关联受空腹血糖效应修饰(交互系数-0.12,P=0.022)。
  • 在较低空腹血糖者中,FGF21与2型糖尿病风险的关联更强。

核心结论

  • 在空腹血糖较低的参与者中,较高的循环FGF21浓度与2型糖尿病发病风险升高独立相关,使循环FGF21浓度成为2型糖尿病的潜在早期生物标志物。

研究设计与样本

  • 研究纳入5244名参与者,年龄52±12岁,50%为男性。
  • 循环FGF21采用Mesoscale U-PLEX检测平台的免疫分析测定。
  • 研究结局为新发2型糖尿病,采用Cox比例风险模型并校正潜在混杂因素。

主要发现

  • 循环FGF21浓度中位数(四分位距)为860(525-1329)pg/mL。
  • 随访7.3(6.1-7.7)年期间,299名(5.7%)参与者发生2型糖尿病。
  • 完全校正分析中,循环FGF21浓度每翻倍与新发2型糖尿病风险升高相关(HR 1.26,95%CI 1.06-1.51,P=0.008)。
  • FGF21与2型糖尿病的关联受空腹血糖效应修饰(交互系数-0.12,P=0.022),在较低空腹血糖者中关联更强。

关键数值与推荐

  • 循环FGF21浓度每翻倍的新发2型糖尿病风险:HR 1.26(95%CI 1.06-1.51,P=0.008)。
  • 空腹血糖交互作用系数:-0.12(P=0.022)。

临床怎么用

  • 原文结论认为循环FGF21浓度是2型糖尿病的潜在早期生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fibroblast growth factor 21 (FGF21) is a peptide hormone synthesized by several organs and regulates, among others, energy homeostasis. In obesity, insulin resistance and type 2 diabetes (T2D), higher circulating FGF21 concentrations have been found. Temporal analyses in murine studies demonstrate that FGF21 increases before insulin resistance occurs. The current study aims to investigate in time-to-event analyses whether FGF21 may be an early biomarker in the development of T2D. RESEARCH DESIGN AND METHODS: Circulating FGF21 was measured using an immunoassay of the Mesoscale U-PLEX assay platform. The study outcome was incident T2D. Associations of circulating FGF21 concentration with T2D were quantified using Cox proportional hazards models with adjustments for potential confounders. RESULTS: We included 5244 participants aged 52 ± 12 years, of whom 50% were male. Median [interquartile range] circulating FGF21 concentration was 860 [525-1329] pg/mL. During 7.3 [6.1-7.7] years of follow-up, 299 (5.7%) participants developed T2D. In fully adjusted analyses, higher circulating FGF21 concentration was associated with an increased risk of incident T2D (hazard ratio per doubling: 1.26 [95% CI, 1.06-1.51]; P = 0.008), with effect modification by fasting plasma glucose, consistent with strengthening of the association at lower fasting glucose (interaction coefficient: -0.12; P = 0.022). CONCLUSION: Higher circulating FGF21 concentrations are independently associated with an increased risk of incident T2D in participants with a low fasting plasma glucose, making circulating FGF21 concentration a potential early biomarker for type 2 diabetes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Post A, Dam WA, Sokooti S, et al. Circulating FGF21 Concentration, Fasting Plasma Glucose, and the Risk of Type 2 Diabetes: Results From the PREVEND Study. J Clin Endocrinol Metab. 2023. PMID: 36533509. doi:10.1210/clinem/dgac729

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。